Physician profile
David M Schlossman
NPI 1790772234
$1,247,985.23
in general payments reported to CMS, 2019-2025
3 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.81 · 2020: $491K · 2021: $219K · 2022: $149K · 2023: $301K · 2024: $89K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $381K · Consulting Fee: $7,410 · Travel and Lodging: $207 · Food and Beverage: $36.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $381,402.84 |
| Consulting Fee | $7,410.00 |
| Travel and Lodging | $206.74 |
| Food and Beverage | $36.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Molecular Systems, INC. | $1,247,945.64 | 2020-2024 | |
| Gilead Sciences, INC. | $27.78 | 2021 | |
| Janssen Biotech, INC. | $11.81 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Schlossman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.